SGLT2 inhibitors – Page 3

Evaluating Dapagliflozin’s Impact on Bone Health in Lupus Nephritis: Insights from a Double-Blind, Placebo-Controlled Trial

By MedXY 10/30/2025

This RCT shows dapagliflozin does not significantly affect bone metabolism or mineral density in lupus nephritis patients over 12 months, alleviating concerns about SGLT2 inhibitors' bone safety in this population.

Cardiology Nephrology news

Dapagliflozin and Cardiac Remodeling in Chronic Kidney Disease: New Evidence for Cardioprotection

By MedXY 10/30/2025

Dapagliflozin reduces left ventricular mass index in chronic kidney disease patients, revealing a key mechanism for cardioprotective effects of SGLT2 inhibitors and highlighting early treatment benefits.

Clinical Updates Diabetes & Endocrinology Neurology news Specialties

Promising Links Between Diabetes Medications and Alzheimer’s Disease Risk Reduction

By MedXY 09/25/2025

Recent real-world data suggest GLP-1 receptor agonists and SGLT2 inhibitors may lower Alzheimer’s disease risk more effectively than DPP-4 inhibitors, highlighting the need for randomized trials to confirm potential neuroprotective benefits.

Clinical Updates Diabetes & Endocrinology news Specialties

Henagliflozin and Aging Biomarkers in Type 2 Diabetes: A Groundbreaking Multicenter Trial Reveals Promising Anti-Aging Effects

By MedXY 09/18/2025

A randomized placebo-controlled trial demonstrates that henagliflozin improves telomere length and multiple aging biomarkers in patients with type 2 diabetes, suggesting potential anti-aging benefits beyond glucose control.

Cardiology Diabetes & Endocrinology Specialties

Dapagliflozin in Hospitalized Heart Failure Patients: Insights from the DAPA ACT HF-TIMI 68 Trial and Meta-Analysis

By MedXY 09/07/2025

In-hospital initiation of dapagliflozin showed a non-significant reduction in cardiovascular death or worsening heart failure at two months. However, meta-analysis supports early SGLT2 inhibitor use for reducing mortality and worsening HF in hospitalized patients.

Clinical Updates Diabetes & Endocrinology Nephrology news Specialties

Long-Term Kidney Protection with SGLT2 Inhibitors in Type 2 Diabetes and CKD: Insights from the DARWIN-Renal Study

By MedXY 08/23/2025

A large real-world study shows that SGLT2 inhibitors significantly slow kidney function decline and improve albuminuria compared with other glucose-lowering drugs in type 2 diabetes patients with chronic kidney disease.

Clinical Updates Diabetes & Endocrinology Specialties

Enhancing Beta-Cell Function and Insulin Sensitivity in Type 2 Diabetes: Insights from Dapagliflozin and Exenatide Combination Therapy

By MedXY 08/23/2025

Dapagliflozin and exenatide independently improve beta-cell function and insulin sensitivity in type 2 diabetes; their combination markedly enhances these effects, suggesting superior glycemic control potential.

Diabetes & Endocrinology Pediatrics Specialties

Adjunct-to-Insulin Therapy Using SGLT2 Inhibitors in Youth with Type 1 Diabetes: Clinical Impact and Renal Outcomes

By MedXY 08/21/2025

SGLT2 inhibitors adjunct to insulin improve glycemic control, reduce hyperfiltration, and are generally safe in youth with type 1 diabetes under careful ketone monitoring and DKA risk mitigation.

Cardiology Diabetes & Endocrinology news Specialties

Oral Semaglutide in Type 2 Diabetes: Efficacy and Safety with and without SGLT2 Inhibitors from the SOUL Trial

By MedXY 08/17/2025

The SOUL trial demonstrates that oral semaglutide significantly reduces major cardiovascular events in type 2 diabetes patients, independently of concurrent SGLT2 inhibitor use, with a favorable safety profile.

Clinical Updates Diabetes & Endocrinology news Specialties Urology

SGLT2 Inhibitors Lower Mortality Risk Post-UTI in Diabetes

By MedXY 08/14/2025

Recent research indicates that patients with type 2 diabetes who use SGLT2 inhibitors after a urinary tract infection have a lower mortality risk compared to those using DPP-4 inhibitors.

Cardiology news Specialties

Anaemia as a Predictor of Iron Dysregulation and Modulator of Empagliflozin Response in Heart Failure with Reduced Ejection Fraction: Insights from the EMPATROPISM-FE Trial

By MedXY 08/13/2025

In patients with heart failure and reduced ejection fraction, anaemia predicts iron homeostasis disruption and influences response to empagliflozin, which increases myocardial iron and improves cardiac function and exercise capacity.

Cardiology Specialties

Evaluating Erythrocytosis Incidence and Thromboembolic Risk in HFrEF Patients Treated with SGLT2 Inhibitors

By MedXY 08/11/2025

This article explores the incidence of erythrocytosis and thromboembolic risk in heart failure patients treated with SGLT2 inhibitors, revealing a higher incidence of erythrocytosis but no associated increase in thromboembolic events over one year.

Cardiology Clinical Updates news Specialties

Dapagliflozin and Spironolactone: A Promising Combination for Heart Failure with Preserved Ejection Fraction

By MedXY 08/11/2025

The SOGALDI-PEF trial evaluates the effects of dapagliflozin combined with spironolactone versus dapagliflozin alone in patients with heart failure, revealing significant improvements in NT-proBNP levels and safety concerns.